
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies is on a positive trajectory, with FDA approval for their diagnostic assay, strategic investments and partnerships, and strong financial performance. Their focus on separating their businesses and expanding in the MRD market, along with their well-validated immune profiling platform, make them a solid investment opportunity for the future.
Bears say
Adaptive Biotechnologies is a promising company in the field of immune-driven medicine, but potential risks make us have a negative outlook on its stock. While gaining FDA approval and expanding into different markets could boost revenue, the stock is currently overvalued and faces risks such as shifts in research and development budgets, dependencies on volatile emerging markets, and potential hurdles in the regulatory process. Additionally, the company plans to separate its Immune Medicine business from its core MRD business, but there is no guarantee this will occur as planned. Financially, the company has strong revenue growth, but the stock is trading at a premium multiple compared to similar companies in the industry.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares